MedTrace Logo

Advancing Student Suicide Interventions With Scalable Technologies

NCT07211373 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-10-17

No results posted yet for this study

Summary

Mobile-based applications, such as JasprHealth, can deliver evidence-based skills intended to reduce imminent suicide risk (e.g., reducing means access), improve emotional states (e.g., via distraction and coaching to act opposite to emotions), and reduce feelings of social isolation (e.g., via shared stories), but user engagement is a barrier. The aim of this study was to examine the effects of a technological application resource (Jaspr) relative to human augmentation (Jaspr+, e.g., motivationally focused orientation plus prompts) on acceptability, preliminary effectiveness, and engagement among college students who screen positive for suicide risk.

Conditions

Interventions

DEVICE

Jaspr

With assistance from a research staff, the subject will complete self-administered suicide risk assessment on the tablet via Jaspr app, then the subject will engage with suicide-related coping skills and resources that the app provides. Subjects will continue to have access to the coping skills and videos via a mobile app.

BEHAVIORAL

Behavioral support

Jaspr conversations will be augmented human-driven behavioral support. Conversations will be guided by motivational interviewing principles. Subjects can sign up to receive JAH mobile app. Subjects will be prompted with their personalized goals as reminders to use the Jaspr app.

Sponsors & Collaborators

  • University of Wisconsin, Madison

    collaborator OTHER

  • University of Massachusetts Chan Medical School, Worcester

    collaborator UNKNOWN

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • University of Massachusetts, Amherst

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-08
Primary Completion
2027-06-30
Completion
2027-06-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07211373 on ClinicalTrials.gov